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doi:10.1016/j.ejvs.2008.12.011Abstract Objectives: To determine the overall operative risk of cardiovascular events in
patients with combined cardiac and carotid artery disease undergoing staged carotid artery
stenting (CAS) and coronary artery bypass grafting (CABG).
Design: Systematic review of operative risks reported in all published studies of CAS plus CABG
procedures.
Results: Eleven eligible, published studies were identified which reported data on 760 CAS plus
CABG procedures. The majority of patients (87%) were neurologically asymptomatic and 82%
had unilateral carotid stenoses. Overall mortality was 5.5% (95% confidence interval, CI: 3.4e
7.6), the risk of suffering an ipsilateral stroke was 3.3% (95% CI: 1.6e5.1) and the risk of suffering
‘any’ stroke was 4.2% (95% CI: 2.4e6.1), while the 30-day risk of myocardial infarction (MI) was
only 1.8% (95% CI: 0.5e3.0). However, the 30-day death and ipsilateral stroke rate was 7.5%
(95% CI: 4.5e10.5) and the 30-day risk of death and any stroke was 9.1% (95% CI: 6.1e12.0), while
the 30-day of death/stroke/MI was 9.4% (7.0e11.8). Cumulative risks in studies where patients
underwent CABG within 48 h of CAS were not higher than in comparable studies where CABG
was delayed by more than 2 weeks.
Conclusions: In a cohort of predominantly asymptomatic patients with unilateral carotid disease,
the 30-day risk of death/any stroke was 9.1%. These data are comparable to previous systematic
reviews evaluating the roles of staged and synchronous carotid endarterectomy (CEA) plus CABG,
and suggest that staged CAS plus CABG is an attractive and less invasive alternative to CEA plus6 2523252; fax: þ44 116 2523179.
.nhs.uk (A.R. Naylor).
ty for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
380 A.R. Naylor et al.CABG. However, it remains questionable whether the observed 9% risks can be justified in any
asymptomatic patient with unilateral carotid disease.
ª 2008 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.There is controversy regarding the optimal management of
patients undergoing coronary artery bypass grafting (CABG)
who are also found to have concomitant severe carotid
artery disease.1 Therapeutic strategies include proceeding
with CABG alone, staged carotid endarterectomy (CEA) plus
CABG,2,3 reverse-staged CEA plus CABG,2,3 synchronous CEA
plus CABG on-pump2,3 and synchronous CEA plus off-pump
CABG (OFF-CABG).4 More recently, staged/synchronous
carotid artery stenting (CAS) plus CABG has emerged as
a newer ‘less invasive’ strategy,5e24 especially following
publication of the SAPPHIRE trial25 which proposed that CAS
was ‘not inferior’ to CEA in patients deemed to be at ‘high
surgical risk’.
We, therefore, performed a systematic review and
meta-analysis of all available published data on the oper-
ative risk of stroke, death and myocardial infarction (MI)
associated with staged/synchronous CAS plus CABG.
Methods
A systematic literature review was undertaken to deter-
mine outcomes following staged CAS plus CABG. Studies
were identified by manual journal reviews, cross-refer-
encing and an electronic PUBMED search using the
advanced search option. A number of combinations of
search terms were used that included one of ‘carotid
stenting’, ‘carotid angioplasty’, ‘coronary surgery’, or
‘bypass surgery’ in combination with one of ‘stroke’,
carotid’ or ‘cardiac’, as appropriate.
Each eligible report was scrutinised by a single researcher
(ARN) and demographic and outcome data extracted.
Demographic data included; (i) preoperative neurological
status (asymptomatic or symptomatic carotid disease, irre-
spective of timing to the staged or synchronous procedure),
(ii) the presence of unilateral or bilateral carotid disease,
(iii) the delay between CAS and CABG, where this was staged
and (iv) peri-procedural antiplatelet strategies.
Perioperative events included any specified endpoint
occurring within 30 days of synchronous CAS plus CABG, or
within 30 days of CABG if this was staged. Endpoints
included: (i) death, (ii) any stroke, (iii) ipsilateral stroke
appropriate to the side of the CAS and (iv) MI. Many
publications have tended to document the rates of death,
stroke and MI as discrete endpoints. However, this does not
necessarily reflect the fact that patients undergoing staged
or synchronous procedures may suffer more than one
discrete cardiovascular event during the perioperative
period. Accordingly, cumulative data have been included in
the reporting of outcomes: (1) mortality, (2) any stroke, (3)
ipsilateral stroke, (4) MI, (5) death with/without ipsilateral
stroke, (6) death with/without any stroke and (7) death
with/without any stroke with/without MI. Not all papers
reported this information, and hence the denominator
differs between analyses. In order to aid data interpreta-
tion, the actual number of patients at risk for each of the
subgroups has been documented in tables.A statistician (ZM) performed all analyses. Risks were
combined across studies allowing for extra-binomial varia-
tion to account for heterogeneity of risk between studies.26
Overall risks with 95% confidence intervals (CIs) were
calculated; confidence intervals for zero observed risks
were estimated with Hanley’s simple formula e ‘the rule of
three’.27 Heterogeneity between studies was calculated as
the sum of the weighted squared deviations of each study
risk from the weighted average risk, weighted by the
inverse of the variance and compared to a c2 distribution.28
Results
Twenty publications were identified between January 1999
and September 2008.5e24 Nine were subsequently exclu-
ded.16e24 Reasons for exclusion included: (i) publication of
single case reports (nZ 416e19), (ii) insufficient or unclear
data (nZ 320e22) and updating of data from the same
centre (nZ 223,24). Eleven studies11e15 describing the
outcome following 760 staged or synchronous CAS plus
CABG procedures were included in the systematic review.
Almost half of the patients (nZ 356) came from one single-
centre series.14 This should be borne in mind when inter-
preting the data as all of the patients in this large series
were neurologically asymptomatic and 94% had a unilateral
carotid stenosis. It should also be noted that a number of
the constituent studies reported that in addition to
undergoing CABG, an additional cardiac procedure was
performed in some patients. Overall, 148 patients in this
systematic review (19%) underwent valve replacement,
redo CABG or (less commonly) some procedure to the aortic
arch, in addition to CABG.
Demographics
The majority of patients in this systematic review (87%)
were neurologically asymptomatic, while 82% had a unilat-
eral carotid stenosis. Table 1 summarises the principal
demographic data from 10 of the constituent studies.
Kramer’s series12 did not provide this information. The
stenosis threshold for recommending intervention varied
between studies. In asymptomatic patients, the majority of
studies used a threshold of greater than 80% for inter-
vening. In recently symptomatic patients, however, the
threshold for intervention varied from more than 50%13 to
more than 75%,7 with no consistency across studies.
CAS methodology
Almost all of the patients underwent primary stenting
(Table 2). Three early studies did not use protective devices
at all,5e7 some were used selectively once they became
available,9 while the remaining eight series used them
routinely once they became available on the market. Two
studies11,13 performed CAS, and the patients then pro-
ceeded immediately to theatre for their CABG. In Kramer’s
Table 1 Demographics of patients undergoing CASþ CABG
Unilateral threshold carotid stenosis
Author Asymp Stenosis Asymptomatic Symptomatic
Mendiz et al.11 25/30 28/30 >80% >70%
Ziada et al.8 30/56 45/56 >80% >70%
Versaci et al.13 29/37 13/37 >80% >50%
Kovacic et al.10 15/23 18/23 >80% >60%
Babatasi et al.5 10/10 6/10 >85% n/aa
Gross et al.6 66/85 62/85 >60% >60%
Van der Heyden et al.14 356/356 334/356 >80% n/aa
Randall et al.9 48/52 32/52 >80% >70%b
Abbasi et al.15 18/28 22/28 No data No data
Lopes et al.7 33/49 32/49 >75% >75%
Kramer’s study12 was not included as it did not provide any of this data.
a No symptomatic patients included.
b If there was a contralateral occlusion, the stenosis threshold for intervention was reduced to >50% in symptomatic patients.
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remaining eight studies, there was a variable period of time
between CAS and CABG ranging from a mean of 9 days7 to
a mean of 70 days.10 In Van der Heyden’s series14 (the
largest published to date), the mean delay to CABG was
22 days (range: 1 day to 3 months).
Perioperative antiplatelet strategy
Table 2 also summarises the different peri-procedural
antiplatelet strategies. Dual antiplatelet therapy (aspir-
inþ clopidogrel/aspirinþ Ticlopidine) was commenced
pre-CAS in seven published series.5e8,10,14,15 The durationTable 2 CAS methodology, antiplatelet strategy and delay to C
Stent CPD Delay to C
Mendiz et al.11 All Since 1999 (nZ 29) Synchrono
Ziada et al.8 All Since 2000 (nZ 8) Mean 39d
Versaci et al.13 All All (nZ 37) Synchrono
Kovacic et al.10 All Since 2000 (nZ 10) Mean 70d
Kramer et al.12 No data No data <48 h
Babatasi et al.5 7/10 None Mean 17d
Gross et al.6 All None Mean 3d (
Van der Heyden
et al.14
All Since 2002 (nZ 143) Mean 2d (
Randall et al.9 47/52 36/52 Range 2e
Abbasi et al.15 All All Range 1e
Lopes et al.7 All None Mean 9d (
asapZ as soon as possible, AZ Aspirin, CZ Clopidogrel, TZ Ticlopid
a 89% of patients also received GpIIBIIIA inhibition following CAS pro
b Prior to 1999, all patients received Aspirin plus Ticlopidine pre-CA
c In the remaining 50%, dual antiplatelet therapy was not stopped.of dual antiplatelet therapy pre-CAS varied from 6 h13 to 8
days.5 Three days of dual antiplatelet therapy prior to CAS
was recommended in Van der Heyden’s series.14 Two
studies gave only aspirin pre-CAS,11,13 presumably because
their patients went directly from the catheter suite to the
cardiac theatre, and there were concerns about excessive
bleeding following CABG. Kramer did not administer any
oral antiplatelet therapy, but all patients received an
intravenous GpIIBIIIA infusion for 6 h prior to CAS.12
Reporting of the duration of dual antiplatelet therapy
following CAS, but before CABG, was inconsistent. No clear
information was provided in four studies,5,7,10,14 Randall
recommended 14 days,9 Ziada 2e3 weeks8 and Gross andABG
ABG Antiplatelet strategy
us A pre-CAS, Aþ C started
asap after CABG
(22) Aþ C pre-CASa and for 2e3 weeks
post-CAS. C stopped pre-CABG
us A for 2d pre-CAS. C started 6 h
post-CABG provided no bleeding
(8e157) Aþ C pre-CAS,b Aþ C stopped 3d prior
to CABG in 50%c
GpIIBIIIA infusion 6 h pre-CAS, Aþ C asap
after CABG
Aþ T for 8d pre-CAS, stopped 7d pre-CABG
6) Aþ T for 2d pre-CAS
and then for 28d. Aþ T stopped pre-CABG
1e3 months) Aþ C for 3d pre-CAS, Aþ C
stopped 5d pre-CABG
60d No mention pre-CAS Aþ C for 14d post-CAS.
2 months A 3d pre-CAS, C added 24 h pre-CAS
and for 28d post-CAS
0e35) Aþ C pre-CAS
and not apparently
stopped for CABG
ine.
cedure.
S.
382 A.R. Naylor et al.Abbassi 28 days.6,15 Similarly, while a number of authors
indicated that they would stop clopidogrel prior to per-
forming a CABG, a number did not indicate any policy
regarding how long before the CABG the antiplatelet agent
should be stopped.6,8,9 Two studies performed CAS imme-
diately prior to CABG, so this question was irrelevant.
Specific recommendations were made by Kovacic et al.10
(clopidogrel stopped 3 days prior to CABG), Van der Heyden
et al.14 (5 days) and Babatasi et al.5 (7 days). Interestingly,
half of Kovacic’s patients proceeded to CABG without
cessation of aspirin and clopidogrel therapy,10 a strategy
also used by Lopes et al.7
Only four of the constituent studies reported major
bleeding complications after staged CAS plus CABG. Van der
Heyden reported one fatal intracranial haemorrhage among
the 356 patients,14 Mendiz et al.11 identified three patients
(out of 10) who required chest re-opening for bleeding (one
of whom later died), Ziada et al.8 observed one groin
haemorrhage requiring surgical exploration (out of 56
patients) while Versaci noted two major cases of early
haemorrhage (cardiac tamponade and re-opening for
bleeding) in 37 patients.13 Thus, in a pooled cohort of 760
patients, only seven major bleeding complications (0.9%)
were reported.
30-day outcomes
There are a number of ways of presenting outcome data.
Some authors have attempted to present separate 30-day
data for CAS and CABG,5,6,9,10,14 although this is obviously
not feasible if the CABG procedure was performed within
30 days of CAS. For the purposes of this systematic review,
outcomes were calculated from the time of CAS to 30 days
after the CABG procedure. This, therefore, includes all
events occurring after CAS (including occasional patients
who never went on to CABG) and all events occurring within
30 days of the cardiac procedure. This is the same format
that has been used in the preceding three systematic
reviews in this series.
Fig. 1 presents forest-plot data from the eligible reports
for discrete outcomes for all patients in the systematic
review, where these events occurred after CAS and within
30 days of the CABG procedure. The overall mortality rate
was 5.5% (95% CI: 3.4e7.6), the risk of suffering an ipsi-
lateral stroke was 3.3% (95% CI: 1.6e5.1) and the risk of
suffering ‘any’ stroke was 4.2% (95% CI: 2.4e6.1), while the
30-day risk of MI was only 1.8% (95% CI: 0.5e3.0). Nine
patients (1.2%) underwent CAS, but did not then undergo
CABG. Four had disabling strokes that followed the proce-
dure,6,14 two patients died after CAS7 while Kovacic et al.10
reported that three patients did not undergo CABG for
reasons ‘unrelated to the CAS’.
Fig. 2 presents forest-plot data from the constituent trials
for combined outcomes for all patients in the systematic
review where these events occurred after CAS and within 30
days of the CABG procedure. The 30-day rate of death/ipsi-
lateral stroke was 7.5% (95% CI: 4.5e10.5), the risk of death/
any stroke was 9.1% (95% CI: 6.1e12.0), while the combined
risk of death/stroke/MI was 9.4% (7.0e11.8%).
Table 3 now includes parallel data from three previous
systematic reviews of synchronous CEA plus CABG, staged
CEA plus CABG, reverse-staged CEA plus CABG andsynchronous CEA plus OFF-CABG.2e4 Data following CAS plus
CABG derived from the current systematic review have
been added for comparison. These data cannot be
compared statistically, but the 30-day outcomes following
CAS plus CABG are not grossly different to those following
synchronous or staged surgical interventions. Note,
however, that the best outcomes were observed in a cohort
of 324 patients undergoing synchronous CEA plus OFF-
CABG.4 Here the 30-day risk of death/stroke was only 2.2%
(95% CI: 0.7e3.7), while the risk of death/stroke/MI was
3.6% (95% CI: 1.6e5.5).
A number of studies in the current systematic review
undertook CABG either immediately after or within 48 h of
performing CAS. It is possible that expedited CABG may
have been associated with poorer outcomes and may have,
therefore, biased the overall data. Table 4 details the
outcomes for death, death/any stroke and death/ipsilat-
eral stroke following CAS plus CABG, stratified for whether
the CABG procedure was staged more than 2 weeks after
CAS or within 48 h of CAS. Once again, these data cannot be
compared statistically, but they do suggest that expedited
CAS plus CABG (<48 h of CAS) was not associated with an
excess cumulative risk compared to that observed with
delayed CABG.
Discussion
This systematic review is the latest in a series of four to
have evaluated morbidity and mortality following a variety
of surgical and interventional strategies in the management
of CABG patients who also have carotid artery disease.1e4
Notwithstanding the heterogeneous nature of the study
cohort and the fact that it is dominated by one large
constituent trial, a mortality rate of 5.5%, an ipsilateral
stroke rate of 3.3%, an ‘any’ stroke rate of 4.2% and an MI
risk of 1.8% has led some to suggest that staged CAS plus
CABG might be a safer alternative to prophylactic CEA.14
However, the cumulative outcome data in Fig. 2 and Table 3
suggest that there is, probably, relatively little difference
in published outcomes regarding CAS plus CABG, compared
with the more traditional synchronous or staged surgical
procedures. However, if this observation is correct, CAS
plus CABG could (because of its less invasive nature)
assume a much greater role in the management of patients
with concomitant carotid and coronary artery disease.
The one obvious caveat would seem to be where the
CABG procedure is performed off-pump (Table 3). Here, the
published results appear more favourable than with any
other management strategy. This finding is important to
document, as one explanation may be that CEA plus OFF-
CABG reduces the risk of post-CABG stroke simply by
avoiding aortic manipulation, dissection and cannulation;
that is, prophylactic CEA may not have contributed to any
significant reduction in the risk of stroke. Although the
presence of carotid disease is an important ‘marker’ of
there being an increased risk of suffering a stroke post-
CABG,1 most studies now suggest that the single most
important cause of stroke after cardiac surgery is athe-
roembolism from the aortic arch.29 It is, therefore, of
interest to observe that the presence of a severe carotid
stenosis is also a very important predictive factor of there
being a high probability of significant atherosclerotic
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
% Risk (95% CI)
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
% Risk (95% CI)
Mendiz 3 / 30 10.0 0.0-23.3
Ziada 3 / 56 5.4 0.0-12.5
Versaci 2 / 37 5.4 0.0-13.5
Kovacic 0 / 20 0.0 0.0-13.9
Kramer 0 / 37 0.0 0.0-7.8
Babatasi 0 / 10 0.0 0.0-25.9
Gross 7 / 85 8.2 2.4-14.1
Van der Heyden 14 / 356 3.9 2.0-6.2
Randall 7 / 52 13.5 5.8-23.1
Abbasi 2 / 28 7.1 0.0-17.9
Lopes 4 / 49 8.2 2.0-16.3
TOTAL 42 / 760 5.5 3.4-7.6
Heterogeneity p= 0.50
Death
Events
Patients
Risk(%) 95% CI
Ipsilateral
stroke
Mendiz 0 / 30 0.0 0.0-9.5
Versaci 1 / 37 2.7 0.0-8.1
Kovacic 1 / 20 5.0 0.0-15.0
Kramer 0 / 37 0.0 0.0-7.8
Babatasi 1 / 10 10.0 0.0-30.0
Gross 5 / 85 5.9 1.2-11.8
Van der Heyden 9 / 356 2.5 1.1-4.2
Randall 4 / 52 7.7 1.9-15.4
TOTAL 21 / 627 3.3 1.6-5.1
Heterogeneity p= 0.67
Risk(%) 95% CI
Events
Patients
Mendiz 0 / 30 0.0 0.0-9.5
Ziada 1 / 56 1.8 0.0-5.4
Versaci 1 / 37 2.7 0.0-8.1
Kovacic 1 / 20 5.0 0.0-15.0
Kramer 0 / 37 0.0 0.0-7.8
Babatasi 1 / 10 10.0 0.0-30.0
Gross 5 / 85 5.9 1.2-11.8
Van der Heyden 11 / 356 3.1 1.4-5.1
Randall 5 / 52 9.6 1.9-17.3
Abbasi 3 / 28 10.7 0.0-25.0
Lopes 4 / 49 8.2 2.0-16.3
TOTAL 32 / 760 4.2 2.4-6.1
Heterogeneity p= 0.52
Stroke
Events
Patients
Risk(%) 95% CI
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
% Risk (95% CI)
Mendiz 1 / 30 3.3 0.0-10.0
Ziada 2 / 56 3.6 0.0-8.9
Kovacic 1 / 20 5.0 0.0-15.0
Kramer 0 / 37 0.0 0.0-7.8
Babatasi 0 / 10 0.0 0.0-25.9
Gross 0 / 85 0.0 0.0-3.5
Van der Heyden 7 / 356 2.0 0.6-3.7
Abbasi 0 / 28 0.0 0.0-10.1
TOTAL 11 / 622 1.8 0.5-3.0
Heterogeneity p= 0.92
MI
Events
Patients
Risk(%) 95% CI
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
% Risk (95% CI)
Figure 1 Forest plots detailing risks of death, any stroke, ipsilateral stroke and MI in the constituent studies. Data relate to the
time from CAS to 30 days after CABG.
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Death /
stroke
Risk(%) 95% CI
Events
Patients
0 2 4 6 8 10 12 14 16 18 20
% Risk (95% CI)
Death /
stroke / MI
Mendiz 3 / 30 10.0 0.0-23.3
Versaci 3 / 37 8.1 0.0-18.9
Kovacic 1 / 20 5.0 0.0-15.0
Kramer 0 / 37 0.0 0.0-7.8
Babatasi 1 / 10 10.0 0.0-30.0
Gross 10 / 85 11.8 5.9-18.8
Van der Heyden 20 / 356 5.6 3.4-8.1
Randall 9 / 52 17.3 7.7-28.8
TOTAL 47 / 627 7.5 4.5-10.5
Heterogeneity p= 0.16
Mendiz 3 / 30 10.0 0.0-23.3
Ziada 4 / 56 7.1 1.8-14.3
Versaci 3 / 37 8.1 0.0-18.9
Kovacic 1 / 20 5.0 0.0-15.0
Kramer 0 / 37 0.0 0.0-7.8
Babatasi 1 / 10 10.0 0.0-30.0
Gross 10 / 85 11.8 5.9-18.8
Van der Heyden 24 / 356 6.7 4.2-9.6
Randall 10 / 52 19.2 9.6-30.8
Abbasi 5 / 28 17.9 3.6-32.1
Lopes 8 / 49 16.3 6.1-26.5
TOTAL 69 / 760 9.1 6.2-12.0
Heterogeneity p= 0.12
Mendiz 4 / 30 13.3 3.3-26.7
Ziada 6 / 56 10.7 3.6-19.6
Versaci 3 / 37 8.1 0.0-18.9
Kovacic 2 / 20 10.0 0.0-25.0
Kramer 0 / 37 0.0 0.0-7.8
Gross 10 / 85 11.8 5.9-18.8
Van der Heyden 31 / 356 8.7 5.9-11.8
Abbasi 5 / 28 17.9 3.6-32.1
TOTAL 61 / 649 9.4 7.0-11.8
Heterogeneity p= 0.33
Risk(%) 95% CI
Events
Patients
0 2 4 6 8 10 12 14 16 18 20
% Risk (95% CI)
Figure 2 Forest plots detailing risks of death/ipsilateral stroke, death/any stroke and death/any stroke/MI in the constituent
studies. Data relate to the time from CAS to 30 days after CABG.
384 A.R. Naylor et al.disease within the aortic arch.30 It, therefore, seems intu-
itive that any strategy that involves minimal mobilisation,
dissection and cannulation of the aortic arch is likely to
reduce the risk of procedural stroke. The relatively small
number of patients undergoing CEA plus OFF-CABG in the
systematic review (nZ 324) allows the reader to only
speculate about whether this is a real finding, or whether it
is simply the result of extreme case selection or publication
bias. Interestingly, no studies (to date) have evaluated
outcomes following CAS plus OFF-CABG.In the interim, how should the data from the current
systematic review be interpreted? One obvious interpreta-
tion will be that the available evidence suggests that staged
CAS plus CABG exhibits similar safety profiles to the more
conventional staged and synchronous surgical procedures.
If true, the less invasive intervention will become an
attractive alternative to those who believe that some sort
of prophylactic carotid intervention is appropriate, espe-
cially in neurologically asymptomatic individuals where
a delay in performing the CABG procedure is more
Table 3 Peri-operative outcomes for synchronous CEAþ CABG, staged CEAþ CABG, reverse-staged CABGþ CEA, synchronous
CEAþOFF-pump CABG and staged CASþ CABG
Operative mortality Death Ipsilat CVA Death any CVA DEATH any CVAMI
(1) Synchronous
CEAþ CABG
CEA pre-bypass
Observed risk 245/5386 307/4189 442/5386 395/3426
Risk% (95%CI) 4.5% (3.9e5.2) 7.3% (6.4e8.2) 8.2% (7.1e9.3) 11.5% (10.1e13.1)
Heterogeneity (pZ) 0.1469 0.0423 0.0000 0.0000
CEA performed on bypass
Observed risk 40/844 52/807 68/844 26/273
Risk% 4.7% (3.1e6.4) 6.4% (4.7e8.2) 8.1% (5.8e10.3) 9.5% (5.9e13.1)
Heterogeneity (pZ) 0.1802 0.3732 0.0770 0.3399
(2) Synchronous CEAþ
off-pump CABG
Observed risk 5/324 5/318 7/318 11/309
Pooled risk (%) 1.5% (0.3e2.8) 1.6% (0.4e2.8) 2.2% (0.7e3.7) 3.6% (1.6e5.5)
Heterogeneity (pZ) 1.00 1.00 1.00 0.99
(3) Staged CEAeCABG
Observed risk 36/917 39/809 56/917 72/709
Risk% 3.9% (1.1e6.7) 4.8% (2.8e6.8) 6.1% (2.9e9.3) 10.2% (7.4e13.1)
Heterogeneity (pZ) <0.0001 <0.0001 <0.0001 <0.0001
(4) Reverse-staged
CABG-CEA
Observed risk 6/302 3/87 22/302 11/221
Risk% 2.0% (0.0e6.1) 3.4% (0.0e9.8) 7.3% (1.7e12.9) 5.0% (0.0e10.6)
Heterogeneity <0.0001 0.0060 <0.0001 0.0102
(5) Staged CASþ CABG
Observed risk 42/760 47/627 69/760 61/649
Risk% 5.5% (3.4e7.6) 7.5% (4.5e10.5) 9.1% (6.2e12.0) 9.4% (7.0e11.8)
Heterogeneity 0.50 0.16 0.12 0.33
Table 4 30-day outcomes following CASþ CABG stratified
for whether CABG was performed <48 h of CAS or >2 weeks
of CAS
Endpoint CABG <48 h of CAS CABG >2 weeks
of CAS
nZ 104 579
Death 5/104 (4.8%
(95%CI 0.0e11.4))
31/579 (5.4%
(95%CI 2.5e8.3))a
Death/
ipsilateral
stroke
6/104 (5.8%
(95%CI 0.0e12.8))
46/523 (8.8%
(95%CI 4.9e12.6))a
Death/any
stroke
6/104 (5.8%
(95%CI 0.0e12.8))
50/579 (8.6%
(95%CI 5.3e11.9))a
Death/stroke/
MI
7/104 (6.7%
(95%CI 0.0e15.2))
39/517 (7.5%
(95%CI 5.4e9.7))a
a Note that the denominator varies between endpoints as not
all studies reported all of this information.
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clopidogrel for a longer period of time). However, the
reader is urged to review the literature more critically
before making this otherwise overly simplistic conclusion.
Previous systematic reviews encountered considerable
bias regarding case mix in studies comparing synchronous
and staged CEA plus CABG.2,3 In one of the largest studies
reporting outcomes following synchronous CEA plus CABG
(nZ 255) and staged CEAeCABG (nZ 257), Takach et al.31
observed that unstable or urgent cases tended to undergo
synchronous operations, while staged interventions tended
to be undertaken in less severe cases. Of most practical
importance is that none of the patients undergoing staged
CEAeCABG in Takach’s series had unstable angina. Such
a degree of case selection will, of course, influence
outcomes.
A similar tendency towards bias is also present in the
current systematic review. Between 80 and 90% of patients
undergoing staged CAS plus CABG were either neurologi-
cally asymptomatic (87%) or had a unilateral carotid
stenosis (82%). Systematic reviews2,3 of patients undergoing
synchronous CEA plus CABG (currently the commonest way
of dealing with coexistent carotid and cardiac disease)
386 A.R. Naylor et al.observed that 39% of patients had a history of prior stroke/
transient ischaemic attack (TIA), while more than a third
(37%) had significant bilateral carotid disease, 25% had left
main-stem coronary artery disease and patients were
generally more likely to be neurologically or cardiologically
unstable. Given the demographics outlined in Table 1, it
would seem that these characteristics are markedly
different to the cohort of individuals who comprise the
majority of patients in the current systematic review.
Accordingly, the crucial question should not be whether
CAS plus CABG is equivalent or even preferable to existing
surgical strategies (it probably is in asymptomatic
patients), but more about whether a 9% procedural death/
stroke rate is likely to confer any significant benefit to the
patient, that is, does the available evidence regarding the
natural history risk of death/stroke in predominantly
asymptomatic CABG patients justify such an excessive risk.
This is not a specific criticism of interventionists as it is
exactly the same question that was posed to surgeons
following two earlier systematic reviews.1e3
The patient cohort comprising the current systematic
review was almost exclusively asymptomatic with unilateral
carotid disease. Because few centres screen for carotid
disease and then not intervene if a severe stenosis is
detected, it is difficult to obtain natural historical data
regarding the risk of stroke in patients undergoing isolated
CABG. In an earlier systematic review focussing on the role
of carotid disease in post-CABG stroke, it was noted that
4674 patients had been screened for carotid disease prior
to undergoing CABG without prophylactic CEA.1 Almost all
of these patients were neurologically asymptomatic. In
patients with no evidence of a carotid stenosis of greater
than 50%, the stroke risk following CABG was 1.8%. The
stroke risk increased to 3.2% in patients with unilateral 50e
99% stenoses, it was 5.2% in patients with bilateral 50e99%
stenoses and only exceeded 10% in patients with a contra-
lateral occlusion.1
The low risk of stroke after isolated CABG in patients with
an asymptomatic carotid stenosis has also been demon-
strated in three other recent studies. In the vascular unit in
Manchester UK, it has been policy to advise against per-
forming prophylactic CEA in any CABG patient with an
asymptomatic carotid stenosis. During the 6-year period
(1995e2000), 50 patients underwent isolated CABG despite
being known to have a 70e99% stenosis (unilateralZ 20,
bilateralZ 30). None of the patients suffered a stroke in the
postoperative period.32 Two other studies reported
outcomes in patients with carotid disease undergoing iso-
lated OFF-CABG. Nakamura described outcomes in 29
patients with significant carotid disease (but no evidence of
impaired cerebral vascular reserve) who underwent isolated
OFF-CABG without suffering any ipsilateral strokes.33 In the
second study, Manabe reported the stroke risk in 49 patients
undergoing OFF-CABG who were known preoperatively to
have carotid disease. Again, none of the patients suffered
a postoperative stroke.34 The data from these three studies,
in conjunction with the findings from the earlier systematic
review, do challenge the assumption that the 9% death/
stroke rate observed in the current CAS plus CABG systematic
review (and in previous systematic reviews of surgical
strategies) can be justified in predominantly asymptomatic
patients with unilateral carotid disease.Notwithstanding our opinion that most CABG patients
with an asymptomatic, unilateral carotid stenosis can
probably undergo their CABG procedure without any
prophylactic carotid intervention (CEA or CAS), we accept
that the treatment of such patients is currently sanctioned
as Grade C evidence in the current American College of
Cardiology (ACC)/American Heart Association (AHA) guide-
lines.35 Hopefully, further guidance will be forthcoming
about what constitutes an acceptable cumulative risk in the
next ACC review, as the risks observed in this and previous
systematic reviews cannot support uncritical continuation
of prophylactic CEA or CAS in patients with asymptomatic
unilateral carotid disease.
A second finding to emerge from this review is the fact
that CABG performed within 48 h of CAS is not associated
with an excessively higher risk as compared with delayed
CABG (>2 weeks). The number of patients in the expedited
group is still relatively small, but it is useful to have
documented that such a strategy is feasible. This may, of
course, represent publication bias and centres with similar
practices are encouraged to publish their results so as to
further inform the debate. The policy regarding peri-
procedural antiplatelet therapy is less clear as this was not
consistently reported across the constituent studies. This is
an omission that requires explicit clarification in future
publications.
In the interim, it is inevitable that an increasing number
of studies are going to be published regarding outcomes
after staged CAS plus CABG. We would, therefore, urge any
potential authors to include the following details in any
planned publication so that future systematic reviews may
be more informative. These include neurological symptom
status, the status of both carotid arteries, a clear expla-
nation of the peri-procedural antiplatelet strategy (type,
duration pre-CAS, minimum duration post-CAS, how long
before (if at all) should clopidogrel be stopped prior to
CABG, how soon can it be restarted post-CABG and how long
post-CABG should dual therapy be continued), a record of
how many patients underwent CAS but suffered a stroke
and who then did not undergo CABG and a clear description
of 30-day outcomes after CABG (death, stroke, ipsilateral
stroke, any stroke or MI). In addition, information should be
provided regarding the cardiac EuroSCORE, the proportion
of patients with stable/unstable angina, single-/multi-
vessel coronary disease, the proportion of patients with left
main-stem disease and the method of performing CABG
(off-pump, on cardiopulmonary bypass, etc.). In particular,
outcomes should be presented first for all patients and then
separately for neurologically asymptomatic and symptom-
atic patients. Stratification should also be included for
patients with unilateral and bilateral carotid disease.
Although some authors may be understandably keen to
demonstrate that most complications happen after CABG
(i.e., CAS was not directly responsible), this is largely
irrelevant as the key endpoints are the cumulative
statistics (death/any stroke, death/ipsilateral stroke or
death/stroke/MI for up to 30 days after CABG). As was
alluded earlier, the issue as to whether CABG should be
performed off-pump merits further consideration, and
centres who have performed staged CAS plus OFFCABG are
encouraged to publish their experience to further inform
the debate.
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